isolated antibody, tumor necrosis factor 25 receptor-specific toxin (tnfr25), method for activating tumor necrosis factor 25 receptor (tnfr25), method for inhibiting tumor necrosis factor 25 receptor (tnfr25) signaling in a cell , antitumor vaccine, method for immunizing a patient against tumor, method for treating cancer in a patient, method for treating and / or preventing intestinal inflammation, therapeutic composition for facilitating an organ transplant, method for transplanting tissue from a donor to a host, method for inhibiting clonal expression of a cognate cd8 t cell population, method for treating and / or preventing pulmonary inflammation, isolated tnfr25 antagonist, composition and expression vector

摘要

ISOLATED ANTIBODY, TOXIN SPECIFICALLY FOR TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25), METHOD FOR ACTIVATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25), METHOD FOR INHIBITING THE NUTRITION OF THE RECEPTOR (25) , ANTITUMORAL VACCINE, METHOD FOR IMMUNIZING A PATIENT AGAINST TUMOR, METHOD FOR TREATING CANCER IN A PATIENT, METHOD FOR TREATING AND / OR PREVENTING INTESTINAL INFLAMMATION, THERAPEUTIC COMPOSITION FOR AN ORGAN TRANSPLANTATION FOR AN ORGAN TRANSPLANTATION HOST, METHOD OF INHIBITING THE CLONAL EXPRESSION OF A POPULATION OF T CD8 COGNATES, METHOD OF TREATING AND / OR PREVENTING PULMONARY INFLAMMATION, ISOLATED TNFR25 ANTAGONIST, COMPOSITION AND EXPRESSION VECTOR. The object of the present invention is to provide new compositions and methods using immunomodulating agents that can stimulate or indirectly increase the immune system or, in other cases, have an immunosuppressive effect. The TNFR25 agonists described herein have an anti-inflammatory and curative effect. They can be used, among other things, to treat disease caused by asthma and chronic inflammation, such as, for example, inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. The TNFR25 antagonists described herein are capable of inhibiting cellular immune responses mediated by the CD8 T cell and can, for example, mitigate organ or tissue rejection after a tissue transplant. The TNFR25 agonists described here represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to strengthen, target or restore the body's ability to fight cancer when administered with anti-tumor vaccines. The specific TNFR25 immunotoxins described here are also capable of increasing the effectiveness of a chemotherapy regimen by depleting naturally occurring immunosuppressive cells in a cancer patient.